Please cite this article in press as: Halberstadt AL. Recent advances in the neuropsychopharmacology of serotonergic hallucinogens. Behav Brain Res (2014), http://dx. doi. org/10. 1016/j. bbr. 2014. 07. 016ARTICLE IN PRESSG Model BBR 9035 1-22 A. L. Halberstadt / Behavioural Brain Research xxx (2014) xxx-xxx 15 [40] Rosenberg DE, Isbell H, Miner EJ, Logan CR. The effect of N,N-dimethyltryptamine in human subjects tolerant to lysergic acid diethylamide. Psychopharmacologia 1964;5:217-27. [41] Abramson HA, Rolo A. Comparison of LSD with methysergide and psilocybin on test subjects. In: Abramson H, editor. The Use of LSD in Psychotherapy and Alcoholism. Indianapolis, IN: Bobbs-Merrill; 1967. p. 53-73. [42] Hollister LE, Macnicol MF, Gillespie HK. An hallucinogenic amphetamine ana-log (DOM) in man. Psychopharmacologia 1969;14:62-73. [43] Lebovits BZ, Visotsky HM, Ostfeld AM. LSD and JB318: a comparison of two hallucinogens. An exploratory study. Arch Gen Psychiatry 1960;2:390-407. [44] Hollister LE, Prusmack JJ, Paulsen JA, Rosenquist N. Comparison of three psy-chotropic drugs (psilocybin JB-329, and IT-290) in volunteer subjects. J Nerv Ment Dis 1960;131:428-34. [45] Haertzen CA, Hill HE, Belleville RE. Development of the Addiction Research Center Inventory (ARCI): selection of items that are sensitive to the effects of various drugs. Psychopharmacologia 1963;4:155-66. [46] Rosenberg DE, Wolbach AB, Miner EJ, Isbell H. Observations on direct and cross tolerance with LSD and d-amphetamine in man. Psychopharmacologia 1963;5:1-15. [47] Isbell H, Jasinski DR. A comparison of LSD-25 with (-)-/Delta19-trans-tetrahydrocannabinol (THC) and attempted cross tolerance between LSD and THC. Psychopharmacologia 1969;14:115-23. [48] Dos Santos RG, Valle M, Bouso JC, Nomdedéu JF, Rodríguez-Espinosa J, Mc Il-henny EH, et al. Autonomic, neuroendocrine, and immunological effects of Ayahuasca. A comparative study with d-amphetamine. J Clin Psychopharma-col 2011;31:717-26. [49] Albertson DN, Grubbs LE. Subjective effects of Salvia divinorum : LSD- or marijuana-like? J Psychoactive Drugs 2009;41:213-7. [50] Mac Lean KA, Johnson MW, Reissig CJ, Prisinzano TE, Grifﬁths RR. Dose-related effects of salvinorin A in humans: dissociative, hallucinogenic, and memory effects. Psychopharmacology (Berl) 2013;226:381-92. [51] Dittrich A. Zusammenstellung eines Fragebogens (APZ) zur Erfassung abnormer psychischer Zustände [Construction of a questionnaire (APZ) for assessing abnormal mental states]. Z Klin Psychol Psychother 1975;23:12-20. [52] Dittrich A. The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. Pharmacopsychiatry 1998;31:80-4. [53] Hermle L, Fünfgeld M, Oepen G, Botsch H, Borchardt D, Gouzoulis E, et al. Mescaline-induced psychopathological, neuropsychological, and neu-rometabolic effects in normal subjects: experimental psychosis as a tool for psychiatric research. Biol Psychiatry 1992;32:976-91. [54] Vollenweider FX, Leenders KL, Scharfetter C, Maguire P, Stadelmann O, Angst J. Positron emission tomography and ﬂuorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology 1997;16:357-72. [55] Gouzoulis-Mayfrank E, Thelen B, Habermeyer E, Kunert HJ, Kovar KA, Lindenblatt H, et al. Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers. Results of an experimen-tal double-blind placebo-controlled study. Psychopharmacology (Berl) 1999;142:41-50. [56] Grob CS, Danforth AL, Chopra GS, Hagerty M, Mc Kay CR, Halberstadt AL, et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry 2011;68:71-8. [57] Strassman RJ, Qualls CR, Uhlenhuth EH, Kellner R. Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale. Arch Gen Psychiatry 1994;51:98-108. [58] Grifﬁths RR, Richards WA, Mc Cann U, Jesse R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal mean-ing and spiritual signiﬁcance. Psychopharmacology (Berl) 2006;187:268-83. [59] Gouzoulis-Mayfrank E, Heekeren K, Neukirch A, Stoll M, Stock C, Obradovic M, et al. Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers. Pharmacopsy-chiatry 2005;38:301-11. [60] Lofwall, Michelle R, Grifﬁths, Roland R, Mintzer, Miriam Z. Cognitive and sub-jective acute dose effects of intramuscular ketamine in healthy adults. Exp Clin Psychopharmacol 2006;14:439-49. [61] Pahnke WN. Psychedelic drugs and mystical experience. Int Psychiatry Clin 1969;5:149-62. [62] Grifﬁths R, Richards W, Johnson M, Mc Cann U, Jesse R. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual signiﬁcance 14 months later. J Psychopharmacol 2008;22:621-32. [63] Grifﬁths RR, Johnson MW, Richards WA, Richards BD, Mc Cann U, Jesse R. Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology (Berl) 2011;218:649-65. [64] Lyvers M, Meester M. Illicit use of LSD or psilocybin, but not MDMA or nonpsychedelic drugs, is associated with mystical experiences in a dose-dependent manner. J Psychoactive Drugs 2012;44:410-7. [65] Studerus E, Gamma A, Vollenweider FX. Psychometric evaluation of the Altered States of Consciousness rating scale (OAV). PLo S ONE 2010;5:e12412. [66] Abramson HA, Jarvik ME, Gorin MH, Hirsch MW. Lysergic acid diethylamide (LSD-25): XVII. Tolerance development and its relationship to a theory of psychosis. J Psychol 1956;41:81-105. [67] Isbell H, Belleville RE, Fraser HF, Wikler A, Logan CR. Studies on lyser-gic acid diethylamide (LSD-25). I. Effects in former morphine addicts anddevelopment of tolerance during chronic intoxication. AMA Arch Neurol Psy-chiatry 1956;76:468-78. [68] Isbell H, Wolbach AB, Wikler A, Miner EJ. Cross tolerance between LSD and psilocybin. Psychopharmacologia 1961;2:147-59. [69] Angrist B, Rotrosen J, Gershon S. Assessment of tolerance to the hallucinogenic effects of DOM. Psychopharmacologia 1974;36:203-7. [70] Abramson HA, Sklarofsky B, Baron MO, Fremont-Smith N. ysergic acid diethy-lamide (LSD-25) antagonists II. Development of tolerance in man to LSD-25 by prior administration of MLD-41 (1-methyl-d-lysergic acid diethylamide). AMA Arch Neurol Psychiatry 1958;79:201-7. [71] Abramson HA, Rolo A, Sklarofsky B, Stache J. Production of cross-tolerance to psychosis-producing doses of lysergic acid diethylamide and psilocybin. J Psychol 1960;49:151-4. [72] Balestrieri A, Fontanari D. Acquired and crossed tolerance to mescaline LSD-25, and BOL-148. Arch Gen Psychiatry 1959;1:279-82. [73] Balestrieri A. Studies on cross tolerance with LSD-25 UML-491 and JB-336. Psychopharmacologia 1960;1:257-9. [74] Appel JB, Freedman DX. Tolerance and cross-tolerance among psy-chotomimetic drugs. Psychopharmacologia 1968;13:267-74. [75] Teresa M, Silva A, Carlini EA, Claussen U, Korte F. Lack of cross-tolerance in rats among (-)/Delta19-trans-tetrahydrocannabinol( /Delta19-THC), cannabis extract, mescaline and lysergic acid diethylamide (LSD-25). Psychopharmacologia 1968;13:332-40. [76] Winter JC. Tolerance to a behavioral effect of lysergic acid diethylamide and cross-tolerance to mescaline in the rat: absence of a metabolic component. J Pharmacol Exp Ther 1971;178:625-30. [77] Wallach MB, Hine B, Gershon S. Cross tolerance or tachyphylaxis among var-ious psychotomimetic agents on cats. Eur J Pharmacol 1974;29:89-92. [78] Colasanti B, Khazan N. Electroencephalographic studies on the development of tolerance and cross tolerance to mescaline in the rat. Psychopharmacologia 1975;43:201-5. [79] Schlemmer Jr RF, Davis JM. A primate model for the study of hallucinogens. Pharmacol Biochem Behav 1986;24:381-92. [80] Shannon M, Battaglia G, Glennon RA, Titeler M. 5-HT1 and 5-HT2 binding properties of derivatives of the hallucinogen 1-(2,5-dimethoxyphenyl)-2-aminopropane (2,5-DMA). Eur J Pharmacol 1984;102:23-9. [81] Lyon RA, Titeler M, Seggel MR, Glennon RA. Indolealkylamine analogs share 5-HT2 binding characteristics with phenylalkylamine hallucinogens. Eur J Pharmacol 1988;145:291-7. [82] Sadzot B, Baraban JM, Glennon RA, Lyon RA, Leonhardt S, Jan CR, et al. Hallucinogenic drug interactions at human brain 5-HT2 receptors: implica-tions for treating LSD-induced hallucinogenesis. Psychopharmacology (Berl) 1989;98:495-9. [83] Mc Kenna DJ, Repke DB, Lo L, Peroutka SJ. Differential interactions of indolealkylamines with 5-hydroxytryptamine receptor subtypes. Neurophar-macology 1990;29:193-8. [84] Glennon RA, Titeler M, Mc Kenney JD. Evidence for 5-HT 2involvement in the mechanism of action of hallucinogenic agents. Life Sci 1984;35:2505-11. [85] Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Bäbler A, Vogel H, Hell D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport 1998;9:3897-902. [86] Carter OL, Burr DC, Pettigrew JD, Wallis GM, Hasler F, Vollenweider FX. Using psilocybin to investigate the relationship between attention, work-ing memory, and the serotonin 1A and 2A receptors. J Cogn Neurosci 2005;17:1497-508. [87] Carter OL, Hasler F, Pettigrew JD, Wallis GM, Liu GB, Vollenweider FX. Psilo-cybin links binocular rivalry switch rate to attention and subjective arousal levels in humans. Psychopharmacology (Berl) 2007;195:415-24. [88] Kometer M, Schmidt A, Bachmann R, Studerus E, Seifritz E, Vollenweider FX. Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors. Biol Psychiatry 2012;72:898-906. [89] Kometer M, Schmidt A, Jäncke L, Vollenweider FX. Activation of serotonin 2A receptors underlies the psilocybin-induced effects on /H9251 oscillations N170 visual-evoked potentials, and visual hallucinations. J Neurosci 2013;33:10544-51. [90] Quednow BB, Kometer M, Geyer MA, Vollenweider FX. Psilocybin-induced deﬁcits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers. Neuropsychopharmacology 2012;37:630-40. [91] Quednow BB, Geyer MA, Halberstadt AL. Serotonin and schizophrenia. In: Müller CP, Jacobs BL, editors. Handbook of the Behavioral Neurobiology of Serotonin. London: Academic Press; 2010. p. 585-620. [92] Hirschhorn ID, Winter JC. Mescaline and lysergic acid diethylamide (LSD) as discriminative stimuli. Psychopharmacologia 1971;22:64-71. [93] Glennon RA, Rosecrans JA, Young R, Gaines J. Hallucinogens as a discrimina-tive stimuli: generalization of DOM to a 5-methoxy-N,N-dimethyltryptamine stimulus. Life Sci 1979;24:993-7. [94] Glennon RA, Titeler M, Seggel MR, Lyon RA. N-methyl derivatives of the 5-HT2 agonist 1-(4-bromo-2,5-dimethoxyphenyl)-2-aminopropane. J Med Chem 1987;30:930-2. [95] Young R, Glennon RA, Rosecrans JA. The hallucinogen DOM as a discriminative stimulus. Commun Psychopharmacol 1981;4:501-4. [96] Glennon RA. Discriminative stimulus properties of the serotonergic agent 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI). Life Sci 1986;39:825-30. 1357 1358135913601361136213631364136513661367136813691370137113721373137413751376137713781379138013811382138313841385138613871388138913901391139213931394139513961397139813991400140114021403140414051406140714081409141014111412141314141415141614171418141914201421142214231424142514261427142814291430143114321433143414351436143714381439144014411442 144314441445144614471448144914501451145214531454145514561457145814591460146114621463146414651466146714681469147014711472147314741475147614771478147914801481148214831484148514861487148814891490149114921493149414951496149714981499150015011502150315041505150615071508150915101511151215131514151515161517151815191520152115221523152415251526